Entering text into the input field will update the search result below

Abcam: Antibody Provider Has Potential, But Is Yet To Deliver

Feb. 09, 2023 3:14 PM ETAbcam plc (ABCM)
Prithvi Vadlamani profile picture
Prithvi Vadlamani


  • Abcam develops antibodies and provides them to life science research firms in the U.S., EMEA, and China.
  • Revenue growth is cyclical, with the highest YoY number at around 24% and the lowest at -2%.
  • Net income is on a downward trend, with current net income TTM (trailing 12 months) of around $9 million.
  • My analysis shows that the stock is overvalued.
  • That significant gap vs. my intrinsic value calculation prompts my hold rating.

Medical Research Laboratory Meeting: Diverse Team of Scientists Use Digital Tablet Computer, Discuss Innovative Biotechnology. Advanced Lab for Medicine, Vaccine Development. Blue Evening Shot


Abcam (NASDAQ:ABCM) has a mixed outlook post-pandemic. Although the firm says it's on the right track with its five-year growth plan, I disagree with certain data provided by the company. The firm is in the life sciences sector, which generally isn't as

Data by YCharts

Abcam PLC Valuation

Abcam PLC Valuation (Self)

Data by YCharts

This article was written by

Prithvi Vadlamani profile picture
Master's in Finance student, passed CFA Level-II.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.